Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.46
+1.2%		$0.38
$0.23
▼
$2.75
$8.80M0.97676,867 shs494,514 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shs1,763 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$0.49
-8.5%		$0.56
$0.43
▼
$3.27
$8.23M1.676,862 shs193,788 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.00
$1.03
$0.31
▼
$1.50
$2.60M1.13,159 shs71 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+1.24%-5.91%+18.07%+64.78%-78.19%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%+100.00%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-8.50%-13.17%-9.26%-42.37%-75.38%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-4.76%0.00%-9.91%+47.06%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.46
+1.2%		$0.38
$0.23
▼
$2.75
$8.80M0.97676,867 shs494,514 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shs1,763 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$0.49
-8.5%		$0.56
$0.43
▼
$3.27
$8.23M1.676,862 shs193,788 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.00
$1.03
$0.31
▼
$1.50
$2.60M1.13,159 shs71 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+1.24%-5.91%+18.07%+64.78%-78.19%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%+100.00%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-8.50%-13.17%-9.26%-42.37%-75.38%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-4.76%0.00%-9.91%+47.06%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
1.80
Reduce$1.00104.08% Upside
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VCNX, ENSC, TRAW, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2026
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/18/2026
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$1.00
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M1.76N/AN/A$0.63 per share0.73
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$2.79M2.70$0.70 per share0.70($0.07) per share-7.00
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K6.70N/AN/A($2.59) per share-0.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$2.76N/AN/AN/A-280.53%-2,550.30%-320.49%11/13/2026 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$9.17M-$1.74N/AN/AN/AN/A-23,868.92%-165.52%11/12/2026 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%11/16/2026 (Estimated)

Latest VCNX, ENSC, TRAW, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$0.3350-$0.16+$0.1750-$0.16N/AN/A
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.20-$0.20N/A-$0.20$1.20 million$1.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.70
0.70
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/A
0.93
0.93
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.95%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.57%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1019.46 million18.91 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
715.37 million14.21 millionNo Data
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3039274/34858/en/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.46 +0.01 (+1.24%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.46 0.00 (-0.24%)
As of 09/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Traws Pharma stock logo

Traws Pharma NASDAQ:TRAW

$0.49 -0.05 (-8.50%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.53 +0.04 (+7.55%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$1.00 0.00 (0.00%)
As of 09/18/2026

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas